(NUS) Nu Skin Enterprises - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US67018T1051
Stock: Beauty Devices, Cosmetics, Personal Care, Supplements
Total Rating 31
Risk 93
Buy Signal -0.74
| Risk 5d forecast | |
|---|---|
| Volatility | 57.7% |
| Relative Tail Risk | -11.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.07 |
| Alpha | -38.66 |
| Character TTM | |
|---|---|
| Beta | 1.533 |
| Beta Downside | 0.466 |
| Drawdowns 3y | |
|---|---|
| Max DD | 85.61% |
| CAGR/Max DD | -0.48 |
EPS (Earnings per Share)
Revenue
Description: NUS Nu Skin Enterprises March 04, 2026
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products globally. The product portfolio includes skincare devices, cosmetics, personal care items, and nutritional supplements. The company operates in the direct selling industry, a business model characterized by a network of independent distributors.
Key product lines include ageLOC LumiSpa, ageLOC TRME, and Beauty Focus. Distribution channels encompass retail stores, online platforms, and independent direct sellers. The companys diverse geographic reach includes Mainland China, South Korea, Southeast Asia/Pacific, the Americas, Japan, Hong Kong/Taiwan, and Europe & Africa. For a deeper dive into Nu Skins financial performance and market position, consider exploring its profile on ValueRay.
Headlines to watch out for
- Direct selling model faces regulatory scrutiny in key markets
- Chinas economic slowdown impacts beauty and wellness product demand
- New product launches like ageLOC LumiSpa drive revenue growth
- Currency fluctuations affect international sales and profitability
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 160.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.50 > 1.0 |
| NWC/Revenue: 19.12% < 20% (prev 13.97%; Δ 5.15% < -1%) |
| CFO/TA 0.06 > 3% & CFO 80.3m > Net Income 160.2m |
| Net Debt (125.6m) to EBITDA (263.5m): 0.48 < 3 |
| Current Ratio: 2.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.9m) vs 12m ago 0.40% < -2% |
| Gross Margin: 69.45% > 18% (prev 0.68%; Δ 6.88k% > 0.5%) |
| Asset Turnover: 103.3% > 50% (prev 117.9%; Δ -14.57% > 0%) |
| Interest Coverage Ratio: 15.14 > 6 (EBITDA TTM 263.5m / Interest Expense TTM 13.9m) |
Altman Z'' 9.68
| A: 0.20 (Total Current Assets 547.7m - Total Current Liabilities 263.7m) / Total Assets 1.41b |
| B: 1.32 (Retained Earnings 1.86b / Total Assets 1.41b) |
| C: 0.15 (EBIT TTM 211.2m / Avg Total Assets 1.44b) |
| D: 2.91 (Book Value of Equity 1.74b / Total Liabilities 600.1m) |
| Altman-Z'' Score: 9.68 = AAA |
Beneish M -3.22
| DSRI: 0.91 (Receivables 39.5m/50.8m, Revenue 1.49b/1.73b) |
| GMI: 0.98 (GM 69.45% / 68.23%) |
| AQI: 0.90 (AQ_t 0.28 / AQ_t-1 0.32) |
| SGI: 0.86 (Revenue 1.49b / 1.73b) |
| TATA: 0.06 (NI 160.2m - CFO 80.3m) / TA 1.41b) |
| Beneish M-Score: -3.22 (Cap -4..+1) = AA |
What is the price of NUS shares?
As of March 17, 2026, the stock is trading at USD 7.21 with a total of 406,501 shares traded.
Over the past week, the price has changed by -3.35%, over one month by -15.67%, over three months by -30.92% and over the past year by -10.40%.
Over the past week, the price has changed by -3.35%, over one month by -15.67%, over three months by -30.92% and over the past year by -10.40%.
Is NUS a buy, sell or hold?
Nu Skin Enterprises has no consensus analysts rating.
What are the forecasts/targets for the NUS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.5 | 4% |
| Analysts Target Price | 7.5 | 4% |
NUS Fundamental Data Overview March 13, 2026
P/E Trailing = 4.4658
P/E Forward = 7.3099
P/S = 0.2369
P/B = 0.4369
P/EG = 0.7782
Revenue TTM = 1.49b USD
EBIT TTM = 211.2m USD
EBITDA TTM = 263.5m USD
Long Term Debt = 204.2m USD (from longTermDebt, last quarter)
Short Term Debt = 38.4m USD (from shortTermDebt, last quarter)
Debt = 364.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 125.6m USD (from netDebt column, last quarter)
Enterprise Value = 602.4m USD (476.8m + Debt 364.3m - CCE 238.6m)
Interest Coverage Ratio = 15.14 (Ebit TTM 211.2m / Interest Expense TTM 13.9m)
EV/FCF = 13.09x (Enterprise Value 602.4m / FCF TTM 46.0m)
FCF Yield = 7.64% (FCF TTM 46.0m / Enterprise Value 602.4m)
FCF Margin = 3.10% (FCF TTM 46.0m / Revenue TTM 1.49b)
Net Margin = 10.79% (Net Income TTM 160.2m / Revenue TTM 1.49b)
Gross Margin = 69.45% ((Revenue TTM 1.49b - Cost of Revenue TTM 453.8m) / Revenue TTM)
Gross Margin QoQ = 70.74% (prev 70.49%)
Tobins Q-Ratio = 0.43 (Enterprise Value 602.4m / Total Assets 1.41b)
Interest Expense / Debt = 1.10% (Interest Expense 3.99m / Debt 364.3m)
Taxrate = 20.34% (3.70m / 18.2m)
NOPAT = 168.2m (EBIT 211.2m * (1 - 20.34%))
Current Ratio = 2.08 (Total Current Assets 547.7m / Total Current Liabilities 263.7m)
Debt / Equity = 0.45 (Debt 364.3m / totalStockholderEquity, last quarter 805.2m)
Debt / EBITDA = 0.48 (Net Debt 125.6m / EBITDA 263.5m)
Debt / FCF = 2.73 (Net Debt 125.6m / FCF TTM 46.0m)
Total Stockholder Equity = 786.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.15% (Net Income 160.2m / Total Assets 1.41b)
RoE = 20.36% (Net Income TTM 160.2m / Total Stockholder Equity 786.7m)
RoCE = 21.31% (EBIT 211.2m / Capital Employed (Equity 786.7m + L.T.Debt 204.2m))
RoIC = 16.46% (NOPAT 168.2m / Invested Capital 1.02b)
WACC = 6.94% (E(476.8m)/V(841.0m) * Re(11.57%) + D(364.3m)/V(841.0m) * Rd(1.10%) * (1-Tc(0.20)))
Discount Rate = 11.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.44%
[DCF] Terminal Value 78.12% ; FCFF base≈55.7m ; Y1≈42.4m ; Y5≈26.0m
[DCF] Fair Price = 9.87 (EV 606.9m - Net Debt 125.6m = Equity 481.3m / Shares 48.8m; r=6.94% [WACC]; 5y FCF grow -28.32% → 2.90% )
EPS Correlation: -26.99 | EPS CAGR: -22.66% | SUE: -0.06 | # QB: 0
Revenue Correlation: -95.71 | Revenue CAGR: -12.27% | SUE: -1.27 | # QB: 0
EPS next Year (2026-12-31): EPS=1.42 | Chg7d=-0.140 | Chg30d=-0.140 | Revisions Net=-1 | Growth EPS=+9.2% | Growth Revenue=+2.1%
P/E Forward = 7.3099
P/S = 0.2369
P/B = 0.4369
P/EG = 0.7782
Revenue TTM = 1.49b USD
EBIT TTM = 211.2m USD
EBITDA TTM = 263.5m USD
Long Term Debt = 204.2m USD (from longTermDebt, last quarter)
Short Term Debt = 38.4m USD (from shortTermDebt, last quarter)
Debt = 364.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 125.6m USD (from netDebt column, last quarter)
Enterprise Value = 602.4m USD (476.8m + Debt 364.3m - CCE 238.6m)
Interest Coverage Ratio = 15.14 (Ebit TTM 211.2m / Interest Expense TTM 13.9m)
EV/FCF = 13.09x (Enterprise Value 602.4m / FCF TTM 46.0m)
FCF Yield = 7.64% (FCF TTM 46.0m / Enterprise Value 602.4m)
FCF Margin = 3.10% (FCF TTM 46.0m / Revenue TTM 1.49b)
Net Margin = 10.79% (Net Income TTM 160.2m / Revenue TTM 1.49b)
Gross Margin = 69.45% ((Revenue TTM 1.49b - Cost of Revenue TTM 453.8m) / Revenue TTM)
Gross Margin QoQ = 70.74% (prev 70.49%)
Tobins Q-Ratio = 0.43 (Enterprise Value 602.4m / Total Assets 1.41b)
Interest Expense / Debt = 1.10% (Interest Expense 3.99m / Debt 364.3m)
Taxrate = 20.34% (3.70m / 18.2m)
NOPAT = 168.2m (EBIT 211.2m * (1 - 20.34%))
Current Ratio = 2.08 (Total Current Assets 547.7m / Total Current Liabilities 263.7m)
Debt / Equity = 0.45 (Debt 364.3m / totalStockholderEquity, last quarter 805.2m)
Debt / EBITDA = 0.48 (Net Debt 125.6m / EBITDA 263.5m)
Debt / FCF = 2.73 (Net Debt 125.6m / FCF TTM 46.0m)
Total Stockholder Equity = 786.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.15% (Net Income 160.2m / Total Assets 1.41b)
RoE = 20.36% (Net Income TTM 160.2m / Total Stockholder Equity 786.7m)
RoCE = 21.31% (EBIT 211.2m / Capital Employed (Equity 786.7m + L.T.Debt 204.2m))
RoIC = 16.46% (NOPAT 168.2m / Invested Capital 1.02b)
WACC = 6.94% (E(476.8m)/V(841.0m) * Re(11.57%) + D(364.3m)/V(841.0m) * Rd(1.10%) * (1-Tc(0.20)))
Discount Rate = 11.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.44%
[DCF] Terminal Value 78.12% ; FCFF base≈55.7m ; Y1≈42.4m ; Y5≈26.0m
[DCF] Fair Price = 9.87 (EV 606.9m - Net Debt 125.6m = Equity 481.3m / Shares 48.8m; r=6.94% [WACC]; 5y FCF grow -28.32% → 2.90% )
EPS Correlation: -26.99 | EPS CAGR: -22.66% | SUE: -0.06 | # QB: 0
Revenue Correlation: -95.71 | Revenue CAGR: -12.27% | SUE: -1.27 | # QB: 0
EPS next Year (2026-12-31): EPS=1.42 | Chg7d=-0.140 | Chg30d=-0.140 | Revisions Net=-1 | Growth EPS=+9.2% | Growth Revenue=+2.1%